Elonva

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

korifollitropin alfa

Available from:

N.V. Organon

ATC code:

G03GA09

INN (International Name):

corifollitropin alfa

Therapeutic group:

Spolni hormoni i modulatori genitalnog sustava,

Therapeutic area:

Reproductive Techniques, Assisted; Ovulation Induction; Investigative Techniques

Therapeutic indications:

Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program. Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG).

Product summary:

Revision: 23

Authorization status:

odobren

Authorization date:

2010-01-25

Patient Information leaflet

                                26
B. UPUTA O LIJEKU
27
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
ELONVA 100 MIKROGRAMA OTOPINA ZA INJEKCIJU
ELONVA 150 MIKROGRAMA OTOPINA ZA INJEKCIJU
korifolitropin alfa
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Elonva i za što se koristi
2.
Što morate znati prije nego počete primjenjivati lijek Elonva
3.
Kako primjenjivati lijek Elonva
4.
Moguće nuspojave
5.
Kako čuvati lijek Elonva
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE ELONVA I ZA ŠTO SE KORISTI
Elonva sadrži djelatnu tvar korifolitropin alfa i pripada skupini
lijekova koji se zovu gonadotropni
hormoni. Gonadotropni hormoni imaju važnu ulogu u ljudskoj plodnosti
i reprodukciji. Jedan od tih
gonadotropnih hormona je hormon koji stimulira folikule (engl.
_Follicle Stimulating Hormone_
, FSH),
koji je potreban u žena za rast i razvoj folikula (malih okruglih
vrećica u jajnicima koje sadrže jajne
stanice) te u adolescentnih dječaka (u dobi od 14 ili više godina)
za liječenje odgođenog puberteta
zbog hipogonadotropnog hipogonadizma u kombinaciji s lijekom koji se
zove ljudski korionski
gonadotropin (engl.
_human Chorionic Gonadotropin_
, hCG).
U žena
Elonva se koristi kako bi se postigla trudnoća u žena koje se
liječe od neplodnosti, na primjer
izvantjelesnom oplodnjom (IVF). Izvantjelesna oplodnja uključuje
sakupljanje jajnih stanica iz jajnika,
oplodnju tih stanica u laboratoriju te prijenos embrija u maternicu
nakon nekoliko dana.
Kontroliranom stimulacijom jajnika Elon
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Elonva 100 mikrograma otopina za injekciju
Elonva 150 mikrograma otopina za injekciju
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Elonva 100 mikrograma otopina za injekciju
Jedna napunjena štrcaljka sadrži 100 mikrograma korifolitropina
alfa* u 0,5 ml otopine za injekciju.
Elonva 150 mikrograma otopina za injekciju
Jedna napunjena štrcaljka sadrži 150 mikrograma korifolitropina
alfa* u 0,5 ml otopine za injekciju.
*korifolitropin alfa je glikoprotein proizveden tehnologijom
rekombinantne DNA u stanicama jajnika
kineskog hrčka (engl.
_Chinese Hamster Ovary_
, CHO).
Pomoćna(e) tvar(i) s poznatim učinkom
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po injekciji, tj.
zanemarive količine natrija.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Otopina za injekciju (injekcija).
Bistra i bezbojna vodena otopina.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Elonva je indicirana za kontroliranu stimulaciju jajnika u kombinaciji
s antagonistom gonadotropin-
oslobađajućeg hormona (engl.
_Gonadotropin Releasing Hormone_
, GnRH) radi poticanja razvoja
višestrukih folikula u žena u sklopu postupka medicinski
potpomognute oplodnje (engl.
_Assisted _
_Reproductive Technology_
, ART).
Elonva je u kombinaciji s ljudskim korionskim gonadotropinom (engl.
_human Chorionic Gonadotropin_
,
hCG) indicirana za liječenje hipogonadotropnog hipogonadizma u
adolescentnih dječaka (u dobi od
14 ili više godina).
4.2
DOZIRANJE I NAČIN PRIMJENE
Liječenje lijekom Elonva u indikaciji kontrolirane stimulacije
jajnika mora se započeti pod nadzorom
liječnika s iskustvom u liječenju problema plodnosti.
Liječenje lijekom Elonva u indikaciji hipogonadotropnog hipogonadizma
mora započeti i nadzirati
liječnik s iskustvom u liječenju hipogonadotropnog hipogonadizma.
Doziranje
_ _
U liječenju žena reproduktivne dobi, doza lijeka Elonva određuje se
na temelju tjelesne težine i dobi.
_-_
_ _
Jedna doza od 100 mikrograma preporučuje se u žena
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 05-04-2023
Public Assessment Report Public Assessment Report Bulgarian 05-07-2022
Patient Information leaflet Patient Information leaflet Spanish 05-04-2023
Public Assessment Report Public Assessment Report Spanish 05-07-2022
Patient Information leaflet Patient Information leaflet Czech 05-04-2023
Public Assessment Report Public Assessment Report Czech 05-07-2022
Patient Information leaflet Patient Information leaflet Danish 05-04-2023
Public Assessment Report Public Assessment Report Danish 05-07-2022
Patient Information leaflet Patient Information leaflet German 05-04-2023
Public Assessment Report Public Assessment Report German 05-07-2022
Patient Information leaflet Patient Information leaflet Estonian 05-04-2023
Public Assessment Report Public Assessment Report Estonian 05-07-2022
Patient Information leaflet Patient Information leaflet Greek 05-04-2023
Public Assessment Report Public Assessment Report Greek 05-07-2022
Patient Information leaflet Patient Information leaflet English 05-04-2023
Public Assessment Report Public Assessment Report English 05-07-2022
Patient Information leaflet Patient Information leaflet French 05-04-2023
Public Assessment Report Public Assessment Report French 05-07-2022
Patient Information leaflet Patient Information leaflet Italian 05-04-2023
Public Assessment Report Public Assessment Report Italian 05-07-2022
Patient Information leaflet Patient Information leaflet Latvian 05-04-2023
Public Assessment Report Public Assessment Report Latvian 05-07-2022
Patient Information leaflet Patient Information leaflet Lithuanian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 05-04-2023
Public Assessment Report Public Assessment Report Lithuanian 05-07-2022
Patient Information leaflet Patient Information leaflet Hungarian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 05-04-2023
Public Assessment Report Public Assessment Report Hungarian 05-07-2022
Patient Information leaflet Patient Information leaflet Maltese 05-04-2023
Public Assessment Report Public Assessment Report Maltese 05-07-2022
Patient Information leaflet Patient Information leaflet Dutch 05-04-2023
Public Assessment Report Public Assessment Report Dutch 05-07-2022
Patient Information leaflet Patient Information leaflet Polish 05-04-2023
Public Assessment Report Public Assessment Report Polish 05-07-2022
Patient Information leaflet Patient Information leaflet Portuguese 05-04-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 05-04-2023
Public Assessment Report Public Assessment Report Portuguese 05-07-2022
Patient Information leaflet Patient Information leaflet Romanian 05-04-2023
Public Assessment Report Public Assessment Report Romanian 05-07-2022
Patient Information leaflet Patient Information leaflet Slovak 05-04-2023
Public Assessment Report Public Assessment Report Slovak 05-07-2022
Patient Information leaflet Patient Information leaflet Slovenian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 05-04-2023
Public Assessment Report Public Assessment Report Slovenian 05-07-2022
Patient Information leaflet Patient Information leaflet Finnish 05-04-2023
Public Assessment Report Public Assessment Report Finnish 05-07-2022
Patient Information leaflet Patient Information leaflet Swedish 05-04-2023
Public Assessment Report Public Assessment Report Swedish 05-07-2022
Patient Information leaflet Patient Information leaflet Norwegian 05-04-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 05-04-2023
Patient Information leaflet Patient Information leaflet Icelandic 05-04-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 05-04-2023

Search alerts related to this product

View documents history